Explore FHI 360

10 Results Found

  • News
    The U.S. President's Emergency Plan for AIDS Relief (PEPFAR) named FHI 360 a winner of the DREAMS Innovation Challenge for the Communities Investing in Education for Child Health and Safety project.
  • Published research
    HPTN 068: A randomized control trial of a conditional cash transfer to reduce HIV infection in young women in South Africa — study design and baseline results
    Young women in South Africa are at high risk for HIV infection. The authors present the design and baseline results from HIV Prevention Trials Network (HPTN) 068, a Phase III trial to assess the effect of a conditional cash transfer on HIV acquisition among young South African women. Interventions, like cash transfers, that address structural factors such as schooling and poverty have the potential to reduce HIV risk in young women in South Africa.
  • Project
    The OPTIONS Consortium represents an international, multidisciplinary partnership of global, regional and country experts across the antiretroviral-based HIV prevention research-to-rollout continuum. The consortium’s goal is to provide...
  • Past Project
    Since 2010, research has demonstrated the efficacy of pre-exposure prophylaxis (PrEP) in reducing HIV acquisition. The U.S. Food and Drug Administration has approved the use of Truvada for HIV prevention, and both the U.S. Centers for Disease...
  • Publication
    July 2010 — The results of the Centre for the AIDS Program of Research in South Africa (CAPRISA) 004 trial of the use of tenofovir gel before and after sex to prevent HIV infection among women in South Africa are presented in an article in the...
  • Project
    FHI 360 partnered with the Centre for the AIDS Programme of Research in South Africa (CAPRISA) at the University of KwaZulu-Natal and with U.S.-based CONRAD to conduct the first study of the effectiveness of a microbicidal product containing an...
  • Publication
    Between 2007 and 2009, FHI 360 conducted three assessment studies of preventing mother-to-child transmission (PMTCT) services in Kenya, Rwanda and South Africa.
  • Past Project
    The FEM-PrEP clinical trial was designed to assess whether a daily dose of the antiretroviral Truvada® is safe and effective at preventing HIV infection among women at high risk of HIV exposure.
  • Past Project
    FHI 360 developed and introduced innovative HIV prevention technologies — including microbicides and antiretrovirals — and worked with local partners to address the need for HIV prevention options, particularly for women.
  • Project
    FHI 360 leads the Regional Prospective Observational Research in Tuberculosis (RePORT) International Coordinating Center (RICC), which manages worldwide research teams.